Effect of curcumin addition to standard treatment on inflammation in endometrial carcinoma

Phase 1

Active, not recruiting

• Conditions: endometrial carcinoma; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2013-001737-40-BE
• Lead Sponsor: Z Leuven

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-06-04
• Study Completion: 2016-03-17
• Last Update Posted: 10 June 2024

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

Endometrial carcinoma, histologically confirmed
No life-threatening metastases

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 5
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5

Exclusion Criteria

Other active malignancy
Documented autoimmune disease
Currently ongoing immunosuppressive therapy
Simultaneous treatment according to other clinical trials
Documented immune deficiency

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Evaluation of inflammatory markers in blood at regular time points<br>Toxicity;Secondary Objective: Time to development of new metastases<br>Response rate<br>;Primary end point(s): Effect on inflammatory mediators in blood;Timepoint(s) of evaluation of this end point: day 0, day 1, day 7, day 14, day 21

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Clinical response;Timepoint(s) of evaluation of this end point: baseline and after standard of care treatment